KOD Insider Trading

Insider Ownership Percentage: 45.30%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $12,452.86

Kodiak Sciences Insider Trading History Chart

This chart shows the insider buying and selling history at Kodiak Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Kodiak Sciences Share Price & Price History

Current Price: $2.63
Price Change: Price Decrease of -0.185 (-6.58%)
As of 04/1/2025 04:41 PM ET

This chart shows the closing price history over time for KOD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$2.81Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Kodiak Sciences (NASDAQ:KOD)

89.06% of Kodiak Sciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KOD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$16Mbought$2.75MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal InflowsTotal Outflows
Kodiak Sciences logo
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Read More on Kodiak Sciences

Today's Range

Now: $2.63
Low: $2.58
High: $2.86

50 Day Range

MA: $4.76
Low: $2.81
High: $8.31

52 Week Range

Now: $2.63
Low: $2.19
High: $11.60

Volume

312,603 shs

Average Volume

355,665 shs

Market Capitalization

$138.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.26

Who are the company insiders with the largest holdings of Kodiak Sciences?

Kodiak Sciences' top insider shareholders include:
  1. John A Borgeson (Insider)
  2. Jason Ehrlich (Insider)
Learn More about top insider investors at Kodiak Sciences.